At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,106 enrolled
Drug / intervention
Laquinimod +1 moredrug
Likely dose
Laquinimod 0.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Jul 31, 2007·Updated Nov 2, 2021
In Brief
A Phase 3 clinical trial evaluating Laquinimod and Placebo for Multiple Sclerosis. Completed, enrolled 1,106 participants across 144 sites in 24 countries.
Detailed Summary
Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesAustria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, Poland, Romania, Russia, Serbia, Spain, Sweden, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartNov 2007
Primary CompletionNov 2010
TodayJul 2026
First PostedJul 31, 2007
Enrollment StartNov 13, 2007
Primary CompletionNov 8, 2010
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 18.9 years ago
Interventions
Laquinimoddrug
Laquinimod 0.6 mg capsule, oral, once daily
Placeboother
oral, once daily, capsule